Modeling and Simulation - PK/PD Archives | 第 28 页，共 37 页

Publication

Inhibitory Effect of Ketoconazole on the Pharmacokinetics of a Multireceptor Tyrosine Kinase Inhibitor BMS-690514 in Healthy Participants: Assessing the Mechanism of the Interaction with Physiologically-based Pharmacokinetic Simulations

BMS-690514, a selective inhibitor of the ErbB and vascular endothelial growth factor receptors, has shown…

Danielle Pillsbury2013 年 2 月 1 日

Publication

Bioavailability of Intranasal vs. Rectal Diazepam

There remains an unmet medical need in the out-of-hospital management of seizure emergencies because older…

Danielle Pillsbury2013 年 2 月 1 日

Publication

Analysis of Level A In Vitro-In Vivo Correlations for an Extended-release Formulation with Limited Bioavailability

A two-stage, numerical deconvolution approach was employed to develop level A in vitro–in vivo correlations…

Danielle Pillsbury2013 年 1 月 21 日

Publication

Pharmacometric Approaches to Guide Dose Selection of the Novel GPR40 Agonist TAK-875 in Subjects with Type 2 Diabetes Mellitus

The G-protein-coupled receptor 40 agonist (GPR40) TAK-875 is being developed as an adjunct to diet…

Danielle Pillsbury2013 年 1 月 9 日

Publication

Absolute Abundance and Function of Intestinal Drug Transporters: A Prerequisite for Fully Mechanistic In Vitro-In Vivo Extrapolation of Oral Drug Absorption

The use of whole body physiological-based pharmacokinetic (PBPK) models linked with in vitro-in vivo extrapolation…

Danielle Pillsbury2013 年 1 月 1 日

Publication

Simulations to Assess Phase 2 Non-inferiority Trials of Different Doses of Capecitabine in Combination with Docetaxel for Metastatic Breast Cancer

A phase II trial in metastatic breast cancer (MBC) (NO16853) failed to show noninferiority (progression-free…

Danielle Pillsbury2012 年 12 月 26 日

Blog Knowledge Base

Calculating Urine PK Parameters

Pharmacokinetic analysis normally focuses on systemic exposure to a drug; however, much can be learned…

Certara2012 年 12 月 6 日

Publication

Novel Biocompatible Disease Modifying Nanomedicine of VIP for Rheumatoid Arthritis

Despite advances in rheumatoid arthritis (RA) treatment, efficacious and safe disease-modifying therapy still represents an…

Danielle Pillsbury2012 年 12 月 4 日

知识库

What Can We Learn from a Human Mass Balance Study?

Mass balance studies are also called “C-14 studies” or “Absorption, Metabolism, and Excretion (AME) studies”.…

Nathan Teuscher2012 年 11 月 27 日

Blog Knowledge Base

生物利用度

Discover bioavailability in pharmacokinetics, its types, the first-pass effect, and calculations. Explore tools for accurate…

Certara2012 年 11 月 4 日

沪ICP备2022021526号

Powered by Translations.com GlobalLink Web Software

Modeling and Simulation – PK/PD

Inhibitory Effect of Ketoconazole on the Pharmacokinetics of a Multireceptor Tyrosine Kinase Inhibitor BMS-690514 in Healthy Participants: Assessing the Mechanism of the Interaction with Physiologically-based Pharmacokinetic Simulations

Bioavailability of Intranasal vs. Rectal Diazepam

Analysis of Level A In Vitro-In Vivo Correlations for an Extended-release Formulation with Limited Bioavailability

Pharmacometric Approaches to Guide Dose Selection of the Novel GPR40 Agonist TAK-875 in Subjects with Type 2 Diabetes Mellitus

Absolute Abundance and Function of Intestinal Drug Transporters: A Prerequisite for Fully Mechanistic In Vitro-In Vivo Extrapolation of Oral Drug Absorption

Simulations to Assess Phase 2 Non-inferiority Trials of Different Doses of Capecitabine in Combination with Docetaxel for Metastatic Breast Cancer

Calculating Urine PK Parameters

Novel Biocompatible Disease Modifying Nanomedicine of VIP for Rheumatoid Arthritis

What Can We Learn from a Human Mass Balance Study?

生物利用度

订阅时事通讯

快捷链接

解决方案

联系我们